Myeloma patients may get a boost from diet and exercise program
NCT ID NCT07236502
First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study tests whether a 16-week lifestyle program focused on nutrition and physical activity can improve physical function, quality of life, and biological aging markers in people with multiple myeloma. About 184 participants will be randomly assigned to either start the program right away or wait 16 weeks. The program includes coaching on eating and exercise habits, with assessments of strength, balance, and blood biomarkers.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- diet and exercise program
- What this could lead to
- If it works, this could point toward a simple lifestyle program to help people with myeloma feel better and move better.
- What could go wrong
- This is a small, early-stage study with no blinding, so results may be influenced by participant expectations. The program requires significant commitment and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 184 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Feb 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adult (≥ 18 years) 2. Diagnosed with MM at least one year prior to study enrollment 3. Has access to a cell phone 4. Be deemed "clinically stable" by their physician guided by the following: 1. no near-term changes in planned myeloma-directed therapy anticipated. (e.g., patient who is 3 months from autologous stem cell transplant just starting on maintenance lenalidomide is eligible since maintenance is planned therapy following transplant) 2. no new significant myeloma symptoms (e.g., fractures) meriting changes in anti-neoplastic therapies; AND 3. stable performance status (ECOG 0-2) 5. No reports of severe pain \> Grade 3 \[defined by the NCI CTCAE as tumor, neurologic, bone, or other pain interfering with self-care ADLs (bathing, dressing, toileting, continence, feeding)\]. 6. Able to participate in moderate PA and strength training per clinician approval and confirmed by participant 7. Able to understand and willing to sign a written informed consent document 8. English proficient for reading and writing Exclusion Criteria: 1. Individuals with \<6 months of life anticipated, coexistent amyloidosis, and/or receiving appetite stimulants will not be approached 2. Fully adherent to the ACS nutrition and physical activity guidelines 3. Currently pregnant or lactating, or anticipating pregnancy 4. On another interventional clinical trial that precludes co-enrollment 5. Psychiatric or other clinical conditions that preclude study compliance 6. Other important medical or safety considerations at the discretion of the investigator(s) and/or approving clinician
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple myeloma (MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Loyola University Chicago
RECRUITINGMaywood, Illinois, 60153, United States
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple-Drug combo aims to deepen myeloma response before transplant
- Cell therapy targets a marker on myeloma cells
- Oral drug combo targets myeloma that escaped the bone marrow
- Can a Four-Drug combo tame Ultra-High-Risk myeloma?
- MRI scans may reveal hidden clues to myeloma relapse risk
- Can a dual immunotherapy erase hidden myeloma cells?